MultiCell has leveraged its proprietary cell technologies to engineer liver cell lines that retain their native functionality, continuously regenerate, and are non-tumorigenic. MultiCell's majority-owned subsidiary, Xenogenics Corporation , is developing the Sybiol synthetic bio-liver device that optimally utilizes MultiCell's proprietary, immortalized human hepatocytes.

MultiCell Technologies, Inc. immortalized human hepatocytes, states that its patented adult stem cell (ASC) is safe from recently announced problems facing embryonic stem cells (ESCs).The tendency for ESC cell lines to become tumorigenic is already a serious setback for their potential as therapeutics. Now, as recently reported by a panel of stem cell experts, scientists say all federally approved lines of embryonic stem cells are contaminated with a non-human molecule. Some experts have projected that the demand for ASCs used in research may increase as a result.